{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Peripheral blood at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}],"title":"Bone marrow at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1","upperLimit":"1000","value":"18"}]}],"title":"Peripheral blood at end of study"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.01","upperLimit":"1250","value":"55"}]}],"title":"Bone marrow at end of study"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Blood samples and bone marrow samples were taken from participants and processed by flow cytometry.","dispersionType":"Full Range","groups":[{"description":"Avelumab 800 mg IV every two weeks in combination with radiation therapy\n\nAvelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle\n\nExternal beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy","id":"OG000","title":"1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and up to end of study for individual patient, an average of 11 months","title":"Percent Change in Aberrant Circulating Plasma Cells in the Peripheral Blood (PB) and Bone Marrow (BM) From Baseline","type":"SECONDARY","unitOfMeasure":"Percent change"}